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ABSTRACT
Introduction: Psoriatic arthritis (PsA) is a
spondyloarthritis that occurs in up to 30% of
psoriasis patients. Patients with PsA are at risk
for decreased quality of life due to both joint
and skin symptoms, impaired physical function
and disease progression. Treatments include
non-steroidal anti-inflammatory drugs,
conventional systemic disease-modifying anti-
rheumatic drugs (DMARDs) such as
methotrexate, and biologic agents, including
tumor necrosis factor-a inhibitors. The most
recently introduced treatment option is
apremilast, an oral phosphodiesterase 4
inhibitor.
Methods: This review provides an in-depth
discussion of apremilast’s mechanism of
action, and evidence of its clinical efficacy and
safety from the Psoriatic Arthritis Long-term
Assessment of Clinical Efficacy (PALACE) phase
III pivotal clinical trials (PALACE 1, 2, and 3).
Results: These trials demonstrate that
apremilast is effective for the treatment of
active PsA, despite prior conventional
DMARDs or biologic treatment. The primary
efficacy end point, a 20% improvement from
baseline in modified American College of
Rheumatology response criteria at Week 16,
was achieved by significantly greater
proportions of patients treated with apremilast
20 mg twice daily (BID) and apremilast 30 mg
BID versus placebo in PALACE 1, 2, and 3.
Improvements in this and other clinical and
patient-reported end points, including swollen
and tender joint counts, Psoriasis Area and
Severity Index score, physical function, and
quality of life, were maintained, extending over
52 weeks of treatment among patients initially
randomized to apremilast. Apremilast’s safety
profile has been acceptable, with diarrhea and
nausea being the most common adverse events,
with no evidence for an increased risk of
infection or need for laboratory monitoring.
The PALACE pivotal data indicate that
apremilast presents a new option for the
treatment of PsA that may be appropriate for
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use early in the treatment ladder. Ongoing
PALACE open-label extension trials of up to
4 years will characterize the long-term clinical
effects and safety of apremilast therapy.
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INTRODUCTION
Psoriatic arthritis (PsA) is an inflammatory
spondyloarthritis associated with psoriasis.
Estimates of PsA prevalence among patients
with psoriasis vary widely (6.6–48.0%) [1, 2]. In
one study that included rheumatologist
assessment, PsA was found in 30% of a sample
of patients with psoriasis [3]. Many individuals
with PsA are undiagnosed [3–5]. In the
Prevalence of Psoriatic Arthritis in Adults with
Psoriasis: An Estimate from Dermatology
Practice (PREPARE) study, 41% of the detected
PsA cases had not been diagnosed before study
entry [3].
PsA is a multi-domain disease, affecting the
musculoskeletal axis, skin, and nails [6–8].
Symptoms of PsA may include joint pain and
swelling, enthesitis, dactylitis and, in those
patients with active skin involvement, itching,
all of which may lead to impaired physical
function, work limitations, emotional distress
and social embarrassment. These disease
manifestations impact patients’ health-related
quality of life (HRQOL) to a similar extent as
other arthropathies and chronic diseases such as
diabetes or heart disease [9–11]. To achieve a
more timely diagnosis of PsA, primary care
physicians and dermatologists may benefit
from education and simple questionnaires that
help identify signs of inflammatory arthritides,
flag signs and symptoms of PsA such as
enthesitis and dactylitis, and identify immune-
modulated joint inflammation [12].
Currently, a range of systemic therapies are
available for the treatment of PsA, including
conventional oral therapies and biologic agents.
Long-term use of these agents may be limited by
safety and tolerability issues, variable efficacy,
route of administration (injection/infusion with
biologic agents) and cost [13–15]. Methotrexate
is among the most widely used conventional
oral therapies [16]. However, evidence of the
effectiveness of methotrexate for treatment of
PsA is limited and conflicting [17–21], and
methotrexate has been associated with risks
of hepatic, pulmonary and bone marrow
toxicity [16]. Biologic agents that act as tumor
necrosis factor (TNF) inhibitors—etanercept,
adalimumab, infliximab, golimumab and
certolizumab—have demonstrated efficacy in
improving the signs and symptoms of PsA in
large, well-controlled clinical studies [12, 14,
22], but patients sometimes experience waning
efficacy over time [13] or rare but serious
adverse events (AEs), such as infection and
non-melanoma skin cancer [14]. Other factors
that limit the use of biologic agents include
injection-related anxiety and cost [15].
Rheumatologists, dermatologists and
patients acknowledge a need for new
medications that show efficacy, can be
tolerated, and are relatively safe. The clinical
successes and unmet needs observed with
conventional oral therapies and biologic
agents have directed research and therapeutic
development, resulting in a search for new
agents that target components of the
pathophysiologic pathways of PsA with fewer
of the limitations characterizing current
treatments.
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APREMILAST
Apremilast (Otezla, Celgene Corporation,
Summit, NJ, USA) is an orally available
phosphodiesterase 4 (PDE4) inhibitor approved
by the US Food and Drug Administration (FDA)
in March 2014 for the treatment of active PsA in
adults, and in September 2014 for the treatment
of moderate to severe plaque psoriasis in
patients who are candidates for phototherapy
or systemic therapy [23]. This review will focus
on the efficacy and safety of apremilast in the
treatment of PsA.
The only known mode of action of apremilast
is selective PDE4 inhibition [24], mediated via
PDE4 binding at apremilast’s dialkoxyphenyl
pharmacophore, a feature shared with other
PDE4 inhibitors [24]. PDE enzymatic activity is
the sole means of cyclic adenosine
monophosphate (cAMP) degradation to AMP in
cells [25]. cAMP is an intracellular secondary
messenger responsible for a wide array of cellular
functions, including regulation of inflammatory
signaling and immune homeostasis [24]. PDE4
comprises a group of isoforms among many in
the PDE enzyme family. In vitro studies
demonstrate that apremilast selectively inhibits
activity of several PDE4 isoforms, including the
long (4B1, 4C1), short (4B2, 4D2) and super-short
(4A1A) isoforms, with no significant inhibition of
other PDEs, cell surface receptors or kinases
(Fig. 1) [24].
Fig. 1 Effect of apremilast on phosphodiesterase (PDE)
enzymatic activity. Enzymatic reactions were carried out in
100 nM cyclic adenosine monophosphate as a substrate,
except for PDE5A1 and PDE9A2 (100 nM cyclic
guanosine monophosphate) and retinal rod PDE6
(100 lM). Data are shown as the mean and standard
deviation (SD) from assays performed in duplicate. Repro-
duced with permission from Schafer et al. [24]
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Each PDE4 isoform is found, in relatively
varying degrees, in immune cells such as
monocytes, T cells and neutrophils [25]. In
human peripheral blood mononuclear cells,
apremilast-mediated PDE4 inhibition, in
response to prostaglandin E2, results in
elevated intracellular cAMP concentrations
[24]. In turn, the apremilast-mediated rise in
cAMP concentrations causes downstream
changes in gene expression via induction of
cAMP response element-binding/activating
transcription factor 1 phosphorylation and
binding to the cAMP response element DNA
sequence, thus driving cAMP response element-
dependent gene expression and inhibition of
nuclear factor-jB transcriptional activity (Fig. 2)
[24].
Specific changes in protein production
observed in human peripheral blood
monocytes with apremilast include inhibition
of lipopolysaccharide-stimulated production of
TNF-a and cytosine phosphodiester-guanine
(CpG) oligonucleotide-stimulated production
of interferon-a [24]. Apremilast did not
Fig. 2 Effect of apremilast on cyclic adenosine monophos-
phate response element-binding protein and nuclear factor-
kappa B (NF-jB) transcriptional activity in a Jurkat T cells
and b T helper 1 (THP-1) monocytic cells at 6 h. All
treatment groups were compared with dimethyl sulfoxide
by one-way analysis of variance (ANOVA) followed by
Dunnett’s multiple comparison post-test (n = 4);
*p\0.05; **p\0.01, ***p\0.001. Effect of apremilast
on NF-jB–driven transcriptional activity in c Jurkat T cells
and d THP-1 monocytic cells at 6 h. All treatment groups
were compared with tumor necrosis factor (TNF)-a c or
lipopolysaccharide (LPS) d by one-way ANOVA followed
by Dunnett’s multiple comparison post-test (n = 4);
***p\0.001 versus TNF-a or LPS. CRE cyclic adenosine
monophosphate response element, SEM standard error of
the mean. Reproduced with permission from Schafer et al.
[24]
4 Rheumatol Ther (2014) 1:1–20
significantly inhibit immunoglobulin G or
immunoglobulin M production in normal
B-cell cultures [24]. In vitro experiments using
CD3-stimulated T cells demonstrate that
apremilast inhibits T-cell-derived cytokines,
including interleukin (IL)-2, IL-5, IL-13, and
IL-17, as well as granulocyte macrophage
colony-stimulating factor (GM-CSF) and
interferon-c (Fig. 3) [24], while expression of
anti-inflammatory mediators IL-10 and IL-6 is
increased with apremilast [26]. Despite its broad
inhibition of inflammatory cytokine
production, other in vitro experiments show
that apremilast has no effect on T-cell or B-cell
clonal expansion or on antibody responses
in vivo using the antigen-specific mouse B-cell
transfer model [24], suggesting that key aspects
of adaptive immune system responses may be
relatively unaffected by apremilast treatment.
In the psoriasis and arthritis in vivo models,
apremilast administration leads to reductions in
epidermal thickening, proliferation and
histologic psoriasiform features [26], and
blocks synovial inflammation, cartilage
damage and bone erosion [27]. Overall, the
broad nature of apremilast-mediated changes to
gene transcription and protein production act
to intracellularly regulate numerous
inflammatory mediators associated with
psoriatic disease [24].
CLINICAL EFFICACY
OF APREMILAST IN PSORIATIC
ARTHRITIS: PHASE III CLINICAL
TRIALS
The effectiveness of apremilast in the treatment
of active PsA in adults has been evaluated in the
Psoriatic Arthritis Long-term Assessment of
Clinical Efficacy (PALACE) phase III clinical
trial program. The PALACE program comprises
4 similarly designed, placebo-controlled trials
(Fig. 4) [28, 29]. PALACE 1, 2, and 3 are pivotal
trials that enrolled patients with active PsA
despite prior conventional disease-modifying
anti-rheumatic drugs (DMARDs) and/or
biologic agents, including a percentage of
biologic efficacy failures (Table 1) [28, 30];
Fig. 3 Apremilast inhibition of Th1, Th2, and Th17
cytokines from primary human T cells stimulated via anti-
CD3 antibody. Results were averaged using data from four
separate T-cell donors. GM-CSF granulocyte macrophage
colony-stimulating factor, IC50 half maximal inhibitory
concentration, IFN-c interferon gamma, IL interleukin,
RANTES regulated on activation, normal T cell expressed
and secreted, SEM standard error of the mean, TNF tumor
necrosis factor. Reproduced with permission from Schafer
et al. [24]
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PALACE 4 enrolled DMARD-naı¨ve patients [29].
Patients were excluded from the PALACE trials
if they had presence of: (1) erythrodermic,
guttate, or generalized pustular psoriasis, or
rheumatic disease other than PsA; (2) a history
of other clinically significant disease or presence
of other major uncontrolled disease; (3) active
tuberculosis, history of incompletely treated
tuberculosis, or significant infection within
4 weeks of screening (no screening for latent
tuberculosis was required); (4) malignancy
(except treated basal cell or squamous cell skin
carcinoma or early forms of cervical carcinoma
with no recurrence in 5 years); (5) alanine
aminotransferase and/or aspartate
aminotransferase [1.5 times the upper limit of
normal (ULN) and total bilirubin [ULN or
albumin \lower limit of normal; and (6) prior
therapeutic failure of [3 agents for PsA or [1
TNF blocker [31]. The PALACE 4 trial will be
discussed in a separate publication. This review
article will focus on the three pivotal PALACE
trials.
In PALACE 1, a total of 504 patients were
randomized and received one or more doses of
placebo, apremilast 20 mg twice daily (BID), or
apremilast 30 mg BID, comprising the intent-to-
treat (ITT) population [30]. As shown in Fig. 4,
patients whose swollen and tender joint counts
had not improved by C20% at Week 16 were
considered non-responders and were required
to be re-randomized (1:1) to apremilast 20 mg
BID or 30 mg BID if they were initially
randomized to placebo, or continued on their
Fig. 4 Overview of the Psoriatic Arthritis Long-term
Assessment of Clinical Efﬁcacy (PALACE) trial design.
*All doses were titrated over the ﬁrst week of treatment.
§Placebo patients whose swollen and tender joint counts
had not improved by C20% were considered non-respond-
ers at week 16 and were required to be re-randomized (1:1)
to apremilast 20 mg twice daily (BID) or 30 mg BID if they
were initially randomized to placebo. Apremilast-treated
patients remained on their initial dose. At week 24, all
remaining placebo patients were re-randomized to apremi-
last 20 mg BID or 30 mg BID. ACR20 American College
of Rheumatology 20, BID twice daily, BSA body surface
area, DMARD disease-modifying anti-rheumatic drug, PD
pharmacodynamics, PK pharmacokinetic. Reproduced with
permission from Gladman et al. [28], Edwards et al. [29]
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initial apremilast dose. At Week 24, all
remaining placebo patients were re-
randomized to apremilast 20 mg BID or 30 mg
BID; all patients received blinded treatment
through to Week 52 [30]. Upon completion of
the 52-week, double-blind period, patients were
eligible to enter a long-term follow-up phase for
a total treatment duration of up to 5 years.
Concomitant use of stable doses of
conventional DMARDs was permitted
throughout the trial [30].
In PALACE 1, at Week 16 in the ITT
population, 20% improvement from baseline
in modified American College of Rheumatology
response criteria (ACR20) [32]—the primary end
point—was achieved by significantly greater
proportions of patients receiving apremilast
20 mg BID [51/168 (30.4%); p = 0.0166] and
apremilast 30 mg BID [64/168 (38.1%);
p = 0.0001] compared with patients receiving
placebo [32/168 (19.0%)] (Fig. 5) [30]. Similar
rates of ACR20 response at Week 16 were
observed in PALACE 2 and 3 (Fig. 5) [33].
Analysis of data from PALACE 1, 2, and 3 also
showed beneficial effects of apremilast at Week
16 on key symptoms of PsA, including swollen
and tender joint counts. Across the three
studies, median percent changes in swollen
and tender joint counts with apremilast 20 mg
BID treatment ranged from -34.9 to 50.0% and
-24.2 to 36.2%, respectively. With apremilast
30 mg BID treatment, median percent changes
in swollen and tender joint counts ranged from
-50.0 to -53.9% and -33.3 to -43.2%,
respectively (Table 2) [31].
The response rates observed in the signs and
symptoms of PsA were maintained among
patients initially randomized to apremilast at
baseline and treated continually over 52 weeks
[33]. ACR20 response rates were generally
sustained over 52 weeks among patients
initially randomized to apremilast in the three
pivotal trials (Fig. 6) [33]. At Week 52, the
proportions of these patients who achieved
ACR20 response ranged from 52.9 to 63.0%
with apremilast 20 mg BID and from 52.6 to
63.0% with apremilast 30 mg BID [33].
Improvements in swollen and tender joint
counts were also sustained over 52 weeks in
these patients. Median percent changes in
Fig. 5 American College of Rheumatology 20 (ACR20)
response at week 16 in the Psoriatic Arthritis Long-term
Assessment of Clinical Efﬁcacy (PALACE) 1, 2, and 3
trials. The intent-to-treat population includes all random-
ized patients who received C1 dose of study medication.
Non-responder imputation was used to handle missing
values. *p\0.05; §p\0.005; p B 0.0001 versus placebo.
BID twice daily. Reproduced with permission from Blanco
et al. [33]
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swollen and tender joint counts with apremilast
treatment 20 mg BID ranged from -78.8 to
-87.5% and from -58.3 to -69.2%,
respectively, across the 3 PALACE trials. Median
percent changes in swollen and tender joint
counts with apremilast 30 mg BID treatment
ranged from -77.8 to -87.5% and -62.5 to
-70.0% across PALACE 1, 2, and 3 (Table 2) [31].
Patient-Reported Outcomes in Psoriatic
Arthritis: Impact of Apremilast
on HRQOL, Including Physical Function
Apremilast improves HRQOL, including
physical function, as observed in the PALACE
trials. In PALACE 1, patients receiving
apremilast exhibited significantly greater
improvements in physical function at Week 16
compared with patients receiving placebo,
based on mean decreases from baseline in
Health Assessment Questionnaire-Disability
index (HAQ-DI) scores (placebo: -0.10;
apremilast 20 mg BID: -0.20, p\0.05;
apremilast 30 mg BID: -0.26, p\0.005)
(Fig. 7) [34]. Similar improvements in HAQ-DI
scores were seen at Week 16 in PALACE 2 and 3
[34]. In PALACE 1, 2, and 3, improvements in
HAQ-DI scores were sustained over 52 weeks in
patients initially randomized to apremilast at
baseline (data not shown) [33].
Sustained improvements in physical
function with apremilast were also
demonstrated in all three PALACE trials based
on changes in subscores on the 36-item Short-
Form Health Survey version 2 (SF-36v2). In
PALACE 1, 2, and 3, sustained improvements
from baseline in the SF-36v2 Physical
Functioning (PF) domain and physical
component summary (PCS) scores were
observed in patients initially randomized to
apremilast [35]. At Week 52, 51.6–64.2% of
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important differences (MCID) of C2.5
improvement, and 66.1–72.7% of patients
achieved SF-36v2 PCS MCID of C2.5
improvement (Table 3) [35].
Enthesitis/Dactylitis and Psoriatic Skin
Measures
Across PALACE 1, 2, and 3, enthesitis was
present in 62.5–64.5% of patients at baseline
and dactylitis was present in 38.7–44.6% of
patients at baseline [36]. In patients with
enthesitis and dactylitis at baseline,
improvements in Maastricht Ankylosing
Enthesitis Score (MASES) and dactylitis count
at Week 16 were observed across all three
studies [36]. Improvements in enthesitis and
dactylitis, as shown by mean changes and
median percent changes in MASES and
dactylitis count, were sustained over 52 weeks
(Figs. 8, 9) (data on file, Celgene Corporation)
[37]. At Week 52, the percentage of patients
who reached a MASES score of zero across the
individual PALACE 1, 2, and 3 studies ranged
Fig. 6 American College of Rheumatology 20 (ACR20)
response over 52 weeks in a patients initially randomized to
apremilast 20 mg twice daily (BID) and b patients initially
randomized to apremilast 30 mg BID (data as observed).
PALACE Psoriatic Arthritis Long-term Assessment of
Clinical Efﬁcacy. Reproduced with permission from Blanco
et al. [33]
Fig. 7 Mean change from baseline in Health Assessment
Questionnaire-Disability Index scores at week 16. The
intent-to-treat population includes all randomized patients
who received C1 dose of study medication. BID twice daily,
PALACE Psoriatic Arthritis Long-term Assessment of
Clinical Efﬁcacy, *p\0.05; §p\0.005 versus placebo,
based on the analysis of covariance model. Reproduced
with permission from Bird et al. [34]
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from 33.3 to 50.7% with apremilast 20 mg BID
and 36.8 to 38.2% with apremilast 30 mg BID
[36]. Similarly, the percentage of patients
achieving a dactylitis score of zero at Week 52
in PALACE 1, 2, and 3 ranged from 57.9 to
75.0% for apremilast 20 mg BID and
63.3–68.9% for apremilast 30 mg BID [36].
In addition, among patients initially
randomized to apremilast at baseline, those
with psoriasis body surface area C3% at
baseline in PALACE 1 experienced sustained
improvement in psoriatic skin symptoms, with
24.5% (apremilast 20 mg BID: 13/53) and 36.8%
(apremilast 30 mg BID: 25/68) achieving 75%
reduction from baseline in Psoriasis Area and
Severity Index (PASI-75) score at Week 52
(Fig. 10) [37]; similar sustained PASI-75
response rates at Week 52 were observed in
PALACE 2 and 3 [37] (Fig. 10).
Placebo patients who were re-randomized to
apremilast at Week 16 or Week 24
demonstrated results in the above efficacy
parameters consistent with those seen in
patients initially randomized to apremilast
(data not shown) [31, 33, 38]. The ongoing
open-label phases of the PALACE trials (Fig. 4)
[37] will provide valuable information about the
long-term efficacy and safety of apremilast
treatment.
APREMILAST SAFETY IN PHASE III
CLINICAL TRIALS
Apremilast has demonstrated an acceptable
long-term safety and tolerability profile in the
PALACE 1, 2, and 3 pivotal trials. In a pooled
analysis of safety from patients in these three
trials [39], a total of 1,493 patients received
study medication and were included in the
safety population (placebo: n = 495; apremilast
20 mg BID: n = 501; apremilast 30 mg BID:
n = 497). The most common adverse events
Table 3 Proportions of PALACE patients achieving MCID in SF-36v2 physical functioning and physical component
summary scores at week 52 (data as observed) [33, 35]
Apremilast
20 mg BID 30 mg BID
PALACE 1 PALACE 2 PALACE 3 PALACE 1 PALACE 2 PALACE 3
Week 52 (data as observed) n = 168 n = 163 n = 169 n = 168 n = 162 n = 167
SF-36v2 (0–100), mean change
PF 7.0 4.1 5.7 5.7 5.0 5.9
PCS 7.8 5.1 6.3 6.5 6.4 5.9
Patients achieving MCID (%)
SF-36v2 PF, C2.5a 64.2 51.6 61.2 60.0 53.9 58.3
SF-36v2 PCS, C2.5a 71.7 66.1 72.7 66.2 69.6 68.3
The n reﬂects the number of randomized patients who received C1 dose of study medication; actual number of patients
available for each parameter may vary
BID twice daily, MCID minimum clinically important difference, PALACE Psoriatic Arthritis Long-term Assessment of
Clinical Efﬁcacy, PCS physical component summary score, PF Physical Functioning subscale, SF-36v2 36-item medical
outcomes survey short-from questionnaire, version 2
a Prespeciﬁed threshold based on the literature at the time of protocol development
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(AEs) during the weeks 0 to C24 apremilast-
exposure period were diarrhea, nausea,
headache, upper respiratory tract infection
(URTI), and nasopharyngitis (Table 4). The
proportion of patients reporting diarrhea,
nausea, and headache appeared to increase in
a treatment- and dose-dependent manner. URTI
and nasopharyngitis were reported more
frequently with either dose of apremilast
compared with placebo, but a dose-related
effect was not observed [39]. The nature and
severity of AEs and the exposure-adjusted
incidence rates were similar in the apremilast-
exposure periods (weeks 0 to C24 and weeks 0 to
C52) [39].
Diarrhea and nausea, the most common
gastrointestinal AEs, occurred most often in the
first 2 weeks of exposure to apremilast, with a
reduced incidence of these AEs after the first
month of dosing [39]. Nausea and diarrhea were
predominantlymildormoderate inseverity in the
weeks 0 to C24 apremilast-exposure period [40].
During the weeks 0 to C52 apremilast-exposure
period, no new severe AEs of diarrhea, nausea,
URTI, or nasopharyngitis were reported after the
weeks 0 to C24 apremilast-exposure period [39].
Serious AEs occurred at low rates, were
comparable across treatment groups (Table 4)
and did not increase with long-term apremilast
exposure based on the exposure-adjusted
Fig. 8 Mean change in Maastricht Ankylosing Spondylitis
Enthesitis Score (MASES) over 52 weeks in a patients with
enthesitis at baseline initially randomized to apremilast
20 mg twice daily (BID) and b patients with enthesitis at
baseline initially randomized to apremilast 30 mg BID
(data as observed); and median percent change in MASES
over 52 weeks in c patients with enthesitis at baseline
initially randomized to apremilast 20 mg BID and
d patients with enthesitis at baseline initially randomized
to apremilast 30 mg BID (data as observed). PALACE
Psoriatic Arthritis Long-term Assessment of Clinical
Efﬁcacy (data on ﬁle, Celgene Corporation). Reproduced
with permission from Kavanaugh et al. [37]
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incidence rates [39]. Exposure-adjusted
incidence rates for serious infections,
including systemic opportunistic infection,
were comparable to placebo [39]. One death
occurred (apremilast 20 mg BID) due to
multiorgan failure, which was considered by
the investigator to be unrelated to apremilast
treatment [39]. Marked abnormalities in clinical
chemistry and hematology laboratory
parameters were mostly transient and
comparable across treatment groups with no
meaningful treatment or dose effect noted
during the apremilast-exposure periods (weeks
0 to C24 and weeks 0 to C52) [39]. Changes in
blood pressure and heart rate were not clinically
meaningful, and no patient had a change from
baseline in Fridericia’s QTc interval[60 ms [39].
Apremilast was associated with weight loss in
PALACE 1, 2, and 3. Weight loss is not
unexpected, as it has been reported with other
PDE4 inhibitors [41]. In these three pivotal
trials, weight decrease was reported as an AE in
1.4% of patients treated with apremilast 20 mg
BID and 1.8% of patients treated with
apremilast 30 mg BID; 0.1% of patients
withdrew from the study because of weight
decrease [42]. In the weeks 0 to C52 apremilast-
exposure period, most patients remained within
±5% of baseline weight (apremilast 20 mg BID:
77.0%; apremilast 30 mg BID: 75.8%); overall,
57.3% patients receiving apremilast 20 mg BID
and 57.1% receiving apremilast 30 mg BID
experienced weight loss [42]. Weight loss did
not lead to any overt medical sequelae or
Fig. 9 Mean change in dactylitis over 52 weeks in
a patients with dactilytis at baseline initially randomized
to apremilast 20 mg twice daily (BID) and b patients with
dactylitis at baseline initially randomized to apremilast
30 mg BID (data as observed), and median percent change
in dactylitis over 52 weeks in c patients with dactylitis at
baseline initially randomized to apremilast 20 mg BID and
d patients with dactylitis at baseline initially randomized to
apremilast 30 mg BID (data as observed). PALACE
Psoriatic Arthritis Long-term Assessment of Clinical
Efﬁcacy (data on ﬁle, Celgene Corporation). Reproduced
with permission from Kavanaugh et al. [37]
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manifestations through the apremilast-
exposure period and was unrelated to nausea
or diarrhea [42].
Investigations in vivo, using a murine
model, and in vitro, using human and murine
cell line investigations, demonstrate an
association between PDE4 inhibition and
decreased adiposity. In PDE4 knockout mice, a
significantly lower level of white fat was seen,
compared with that in wild-type controls;
brown fat levels were unaffected [43].
Moreover, PDE4 inhibition has been linked to
enhanced cellular cholesterol efflux, by
inducing expression of the transporter ABCA1;
increases in ABCA1 were also associated with
increases in high-density lipoprotein plasma
concentrations [44]. Given the weight loss
observed in PALACE 1, 2, and 3, body weight
should be monitored during apremilast
treatment in all patients; unexplained or
clinically significant weight loss may warrant
discontinuation of apremilast [23].
PDE4 inhibitors such as roflumilast have also
been associated with an increase in AEs of
depression and suicidal ideation and behavior
[41]. In the pooled safety analysis of PALACE 1,
2, and 3, depression or depressed mood was
reported in 1.0% (10/998) of patients treated
with apremilast compared with 0.8% (4/495) of
patients treated with placebo during the
16-week placebo-controlled period [23].
Instances of suicidal ideation and behavior
were observed in 0.2% (3/1,441) of patients
receiving apremilast compared with no patients
receiving placebo (0/495) during the 16-week
placebo-controlled period [39]. In a larger
pooled analysis from clinical trials of
apremilast in patients with PsA, psoriasis or
rheumatoid arthritis, two patients receiving
placebo committed suicide, whereas no
apremilast-treated patients did so [23, 39].
Because depression is frequently comorbid
with psoriatic disease [45], it will continue to
be challenging to differentiate disease-related
versus treatment-related risks of depressive
disorders and suicidal ideation/behaviors.
PRACTICAL POINTS: APREMILAST’S
PLACE IN THERAPY
Currently available algorithms for PsA
treatment guide clinicians through treatment
choices, beginning with non-steroidal anti-
inflammatory drugs, followed by conventional
Fig. 10 Seventy-ﬁve percent reduction from baseline Pso-
riasis Area and Severity Index (PASI-75) response over
52 weeks in patients with C3% body surface area at baseline
in a patients initially randomized to apremilast 20 mg twice
daily (BID) and b patients initially randomized to
apremilast 30 mg BID (data as observed). n/m number of
responders/number of patients with sufﬁcient data for
evaluation, PALACE Psoriatic Arthritis Long-term Assess-
ment of Clinical Efﬁcacy. Reproduced with permission
from Kavanaugh et al. [37]
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oral DMARDs, followed by biologic agents [46].
Apremilast is a new treatment option that
relieves the pain and inflammation of PsA
while improving physical function. As a PDE4
inhibitor, it presents a new mechanism of
action for the treatment of PsA.
The efficacy and safety profile of apremilast
suggests it may be appropriate for use early in
the treatment ladder, comparing favorably with
conventional oral therapies and biologic agents.
Compared with conventional oral therapies,
apremilast exhibits a favorable safety profile
and is more convenient, with no lifestyle
modifications, pre-screening or ongoing
laboratory monitoring required. Compared
with biologic agents, apremilast is available
orally, thus there is no need for injection, it
may be more convenient to prescribe, and it has
no apparent increased risk of serious infection
or malignancy in clinical trials.
Given the clinical benefits observed in
patients with PsA, apremilast has been
evaluated in psoriasis and based on this, has
been approved by the FDA on September 23,
2014 for the treatment of moderate to severe
plaque psoriasis in patients who are candidates
for phototherapy or systemic therapy. The
Efficacy and Safety Trial Evaluating the Effects
of Apremilast in Psoriasis (ESTEEM) study is a
phase III clinical trial program comprising two
randomized, placebo-controlled studies
evaluating the efficacy, safety and tolerability
of apremilast in the treatment of patients with
moderate to severe plaque psoriasis. Both
ESTEEM 1 and 2 demonstrated the efficacy of
apremilast 30 mg BID over 16 weeks in patients
with moderate to severe plaque psoriasis
[47–49]. Response was generally maintained in
patients who continued for 52 weeks in the
maintenance phases of these trials [48, 50]. The
open-label extension studies will provide
additional valuable information about the
long-term efficacy and safety of apremilast for
the treatment of psoriasis.
CONCLUSION
Apremilast is a PDE4 inhibitor for the treatment of
active PsA in adults. In the phase III PALACE trials,
apremilast demonstrated efficacy in the signs and
symptoms of PsA as well as improvements in
physical function and HRQOL, which were
generally sustained over 52 weeks of treatment.
Ongoing PALACE open-label extension trials of
up to 4 years in duration will provide valuable
information regarding the long-term clinical
effects and safety of apremilast therapy in PsA;
the ESTEEM trials are investigating apremilast for
the treatment of psoriasis. The safety and
tolerability profile of apremilast indicates no
need for laboratory monitoring. With an
alternative mechanism of action, oral route of
administration and comparatively favorable
safety profile, apremilast presents a new
treatment option for PsA that may be
appropriate for use early in the treatment ladder.
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